You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Validating the MicroKine Assay for Use in Identifying Personalized Precision Therapies for Pediatric Sepsis
SBC: PreDxion Bio, Inc. Topic: NICHDProject Summary Abstract PreDxion BioLLC is a precision medicine diagnostic company developing an assay platformthe MicroKineassay cartridge and readerthat measures serum proteins in less thanminutes from a single drop of bloodThis fastactionable information allows for the first time individualized precision medicine aimed at reducing pediatric morbidity and mortality in pediatric sepsisthe number ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
An Engineered Nanoimmunotherapy for Melanoma
SBC: IMMUNOBLUE, LLC Topic: NCIPROJECT SUMMARY Melanoma is one of the most prevalent cancers and is estimated to account for overdeaths inin the United States aloneAlthough highly curable when detected earlytheyear survival rates decline precipitously for patients with regionaland metastaticmelanoma indicating a lack of efficacy of conventional therapiesand a strong need for novel therapies for this patient populationIn respons ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Building an evidentiary case for circulating GHBP as a biomarker for drug-associated stunting of growth
SBC: REVERAGEN BIOPHARMA, INC. Topic: NICHDThere is increasing interest in the use of biomarkers in clinical drug developmentwith much of thest Century Cures Act focused on encouraging this approachIdeallybiomarkers could provide and acute and objective read out of drug mechanism of actionpharmacodynamic biomarkersor prediction of later clinical benefit or harmsurrogate outcome measureHoweververy few biomarkers have been validated for rout ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Noninvasive placement and activation of deep-brain stimulating magnetic particles for reduction of drug-seeking behaviors
SBC: WEINBERG MEDICAL PHYSICS, INC. Topic: NIDAAbstract Deep brain stimulationDBSwith implantable electrodes has been used for reduction of ethanol abuse and drug seeking behaviors in EuropeThe use of such deep brain stimulation procedures has been problematic because of concerns about invasiveness of the procedureApplicant has developed a new noninvasive method of transporting magnetic particles directly to target sites within the brainWe pro ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Infant NeuroLUX: A Novel Non-invasive Therapeutic Device for Neonatal Hypoxic Brain Injury
SBC: Mitovation, Inc. Topic: 101Neonatal hypoxia ischemia is a known cause of cerebral damage resulting from inadequate blood flow and or oxygen delivery to the infant brain beforeduringor after birthThe occurrence among hospital deliveries isperfull term births with a drastic increase among premature newbornsThe deficit in oxygen delivery to the brain results in extensive damage and severe disabilitiesRestoration of blood flow ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Nucleobase aminosugars with reduced ototoxicity
SBC: NUBAD LLC Topic: YPROJECT SUMMARYAminoglycosides are one of the cheapest and well known antibiotics in clinical use for overyearsbut one of the major limitations in their use is their ototoxicityWe are developing fast and low cost methods to develop aminoglycosides with antiribosomal activities and reduced toxicityIn this projectwe will identify novel aminoglycoside antibacterialsthat show reduced ototoxicityComple ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Embryonic stem cell high throughput screen accurately reports toxic stress
SBC: REPRODUCTIVE STRESS MEASUREMENT MECHANISMS & MANAGEMENT CORP Topic: NIEHSState of the art techniques in Developmental and Reproductive Technology use slowexpensive testing of pregnant female rodentsor of embryonic stem cellsESCsthat are cultured to lose stem cell qualities and differentiate into organ tissuesThis only produces toxicological outcomes similar to those in adult versions of these organsReproductive StressM has established high throughput screensHTSsthat te ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Preclinical Development of 2nd Generation HIV Maturation Inhibitors
SBC: DFH Pharma, Inc Topic: 400Project SummaryDespite advances in the development of HIV drugs there remains a need for new therapiesToxicities associated with long term use of many of the approved HIV drugs coupled with the development of resistance drives the need for new and novel antiviralsMaturation inhibitorsMIsrepresent one such class of HIV therapiesHIV maturation inhibitors block virus replication by disrupting the con ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Therapeutic inhibition of Fas-mediated retinal cell death and inflammation in dry AMD
SBC: ONL Therapeutics, Inc. Topic: NEIPROJECT SUMMARYABSTRACT Age related macular degenerationAMDis the leadingand due to the aging baby boomersa growing cause of irreversible vision loss in the United Statesand is strongly associated with exposure to cigarette smokeCSand high fat dietsHFDWhile effective treatment is available for neovascular AMDthe AREDS II antioxidant vitamins are the only proven treatment for intermediate dry AMDUn ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Targeted Nanotherapy to Donor Organ Endothelia Modulates Early Immune Responses and Protects Against Late Graft Failure
SBC: ToleRaM NanoTech LLC Topic: NIBIBABSTRACT Transplantation is an accepted and highly successful therapy for end stage organ diseaseWhile success rates and survival have risen steadilydue largely to improved immunosuppression regimesthere is a growing appreciation that damage and inflammation that occur early in the life of the graftsignificantly impact chronic rejection and thus long term survivalCentral to these early event injur ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health